Researchers have uncovered a novel mechanism utilized by group A streptococcus that allows it to evade detection by the immune system in infected mice, providing insight for the development of effective countermeasures against this pathogen.
Scientists investigating increased scarlet fever cases have identified that a new dominant linage of Strep A with increased toxin production has emerged.
A cohort of scientists from the Wellcome Sanger Institute, the University of Cambridge, the Peter Doherty Institute for Infection and Immunity and the University of Queensland have identified novel targets using DNA sequencing, bringing research one step closer to developing a universal vaccine against Group A Streptococcus.
A new study has investigated whether a 6-day course of antibiotics will give the same outcomes as a 12-day course for treating cellulitis, demonstrating that long-term outcomes may differ.
Researchers have demonstrated that the genetic variation between strains could explain the clinical variation among individuals infected with the same pathogen.
New research has highlighted the burden of group B streptococcal disease in women and infants worldwide, highlighting the need for a vaccine.
Researchers have discovered that a leaderless intercellular peptide signal may contribute to group A Streptococcus virulence; providing a framework for the identification in other microorganisms that may potentially serve as therapeutic targets.
Researchers have discovered that some oligosaccharides from human breast milk may possess antimicrobial and anti-biofilm properties against Group B Streptococcus (GBS).
New research suggests that blood vessels are unable to clear infection due to the lack of ubiquitination that takes place in the endothelial cells.
In this exclusive piece the authors discuss the choice of peptide antigen, delivery system/adjuvant and delivery route as key factors in the development of an effective human vaccine against group A Streptococcus.